Hydrocodone Bitartrate

CHEMBL3989677 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

989.0 g/mol

LogP

—

Phase

4

The bitartrate salt form of hydrocodone, an opioid analgesic used for moderate to severe pain management and antitussive purposes. This salt form improves stability and solubility in oral formulations. Like all opioids, it carries significant risks of respiratory depression, dependence, and misuse.

Moleküler Ağırlık

989,0000 g/mol

TPSA

313,00 Å²

Terapötik Alanlar

Pain Management Obesity Lymphoma Breast Cancer Chronic Pain

Etki Mekanizması

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O

InChI

InChI=1S/C18H21NO3.C4H6O6.2H2O/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10;;/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10);2*1H2/t11-,12+,17-,18-;;;/m0.../s1

Molecular Formula

C44H64N2O23

HBD / HBA

13 / 25

Döndürülebilir Bağlar

8

Ağır Atomlar

69

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The bitartrate salt form of hydrocodone, an opioid analgesic used for moderate to severe pain management and antitussive purposes. This salt form improves stability and solubility in oral formulations. Like all opioids, it carries significant risks of respiratory depression, dependence, and misuse.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Hydrocodone Bitartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989677. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23724881. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Hydrocodone Bitartrate PillFYI'da

Yapı

Hızlı Veriler

Formül: C44H64N2O23
Eş Anlamlılar: 19

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.